MUSE Microscopy Launches Innovative Digital Pathology for Vets

IRVINE, Calif., June 9, 2025 – MUSE Microscopy, Inc., a leader in digital pathology innovation, has officially launched MUSE Veterinary Digital Pathology, LLC, a wholly-owned subsidiary that aims to revolutionize veterinary diagnostics through point-of-care services. The new initiative promises to deliver same-day results for tissue biopsies, marking a significant advancement in veterinary medicine's diagnostic capabilities.

The formation of MUSE Veterinary Digital Pathology represents MUSE's strategic entry into the veterinary health market, leveraging its proprietary SmartPath MUSE Technology™ platform, which enables rapid, non-destructive tissue imaging. According to Matthew Nunez, CEO of MUSE Microscopy, "This launch represents a natural and strategic expansion of our technology platform. The veterinary sector is primed for innovation in diagnostic speed and precision."

The SmartPath system is designed to facilitate real-time treatment decisions by providing veterinarians with immediate diagnostic results, thereby enhancing patient care for pets. This innovation is expected to primarily benefit specialty, emergency, and family veterinary practices across the United States, with operations set to commence in the fourth quarter of 2025.

Darin Nelson, who joins MUSE as President, brings a wealth of experience from his previous roles at VCA and Thrive Pet Healthcare, where he was instrumental in scaling veterinary diagnostic services. Nelson commented, "Our goal is to enable faster decision-making, minimize wait times, and ultimately improve clinical outcomes for animal patients."

Additionally, Dr. Jeffrey Edwards, DVM, MPH, MRVCS, DAVCP, has been appointed as Chief Medical Officer, overseeing the anatomic pathology team and ensuring the effective integration of the new technology within veterinary practices. Dr. Edwards emphasized the importance of this innovation, stating, "Veterinary medicine is long overdue for this level of innovation. With our groundbreaking technology, we can reduce the delay in receiving biopsy results that currently take 3-7 days down to same-day diagnosis."

MUSE Veterinary Digital Pathology will operate independently but will utilize MUSE Microscopy’s existing infrastructure and regulatory framework. The company anticipates announcing pilot partnerships and distribution opportunities both domestically and internationally in the coming months.

The launch of MUSE Veterinary Digital Pathology holds significant implications for the veterinary industry, potentially transforming the standard of care for animal patients. By integrating advanced digital pathology tools directly into veterinary practices, the initiative aims to alleviate the anxiety pet owners face while waiting for critical diagnostic results and improve overall clinical outcomes. As the industry embraces this technology, stakeholders are optimistic about the potential for enhanced diagnostic speed and precision, paving the way for a new era in veterinary medicine.

For further details on MUSE Microscopy, visit their official website at [musemicroscopy.com](https://musemicroscopy.com/). Please note that the SmartPath MUSE Technology™ is pending FDA approval and further developments are expected in the near future.